CTOs on the Move

Nura Inc

www.nura.com

 
Nura Inc is a Seattle, WA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.nura.com
  • 1124 Columbia St Ste 650
    Seattle, WA USA 98104
  • Phone: 206.344.2101

Executives

Name Title Contact Details

Similar Companies

Relay Technology Management

Relay has developed a proprietary software solution for stakeholders of the biopharmaceutical technology licensing and development process.

Active Motif

Active Motif is a fast-growing biotechnology company that is dedicated to developing new and innovative tools and techniques that help analyze nuclear function. Our employees are our biggest asset and our corporate policy is to treat them as such. This

Celldex

Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body`s immune response. Celldex Therapeutics (NASDAQ: CLDX) was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. The Company`s pipeline is comprised of therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers, including many underserved or completely un-served orphan indications. This has created a leading pipeline in immuno-oncology.

Nano-C

Nano-C is a Westwood, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Chiron

Chiron Corporation was an American multinational biotechnology firm founded in 1981, based in Emeryville, California, that was acquired by Novartis on April 20, 2006.